Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 1

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

NCT03475212 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in patients that have a primary immunodeficiency disorder with no prior stem cell transplant.

Interventions

  • BIOLOGICAL Virus Specific T-cell (VST) infusion

Study Locations (20)

California

  • City of Hope — Duarte
  • University of California, Los Angeles — Los Angeles
  • Children's Hospital Los Angeles — Los Angeles
  • Stanford Lucile Packard Children's Hospital — Palo Alto
  • UCSF Medical Center — San Francisco

Massachusetts

  • Tufts Medical Center — Boston
  • Dana-Farber Cancer Institute/ Boston Children's Hospital — Boston

Michigan

  • University of Michigan — Ann Arbor
  • Spectrum Health - Helen DeVos Children's Hospital — Grand Rapids

New York

  • Roswell Park Comprehensive Cancer Center — Buffalo
  • Columbia University Medical Center — New York

Arizona

  • Phoenix Children's Hospital — Phoenix

Colorado

  • Children's Hospital Colorado — Aurora

Connecticut

  • Yale — New Haven

District of Columbia

  • Children's National Medical Center — Washington D.C.

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2018-06-20
Est. Completion 2025-06-30
Phase Phase 1

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03475212

The ClinicalTrials.gov registry entry for NCT03475212 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Transplantation & Cellular Therapy Consortium, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention — of which Virus Specific T-cell (VST) infusion is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03475212 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Massachusetts, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03475212 about?

NCT03475212 is a clinical study titled "Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation". The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in patients that have a primary immunodeficiency disorder with no prior stem cell...

What is the current status of trial NCT03475212?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2018-06-20. Estimated completion is 2025-06-30.

What conditions does trial NCT03475212 study?

This clinical trial studies the following conditions: Cytomegalovirus Infections, Adenovirus Infection, EBV Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03475212?

The interventions under investigation include: Virus Specific T-cell (VST) infusion (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03475212?

This trial is sponsored by Pediatric Transplantation & Cellular Therapy Consortium, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03475212 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial